The Metastatic Prostate Cancer Project: listen to the program

Yesterday evening we were pleased to be able to collaborate with CureTalks to host a conversation with Dr. Eli Van Allen — the principal investigator for the Metastatic Prostate Cancer Project — to “spread the word” about this initiative. … READ MORE …

CureTalk with Dr. Eli Van Allen on the “Metastatic Prostate Cancer Project”

On Wednesday, February 21, at 5:00 p.m. Eastern time (2:00 p.m. Pacific), we will be collaborating with CureTalks to present the next CureTalk on prostate cancer. It will address the recently launched “Metastatic Prostate Cancer Project”. … READ MORE …

What did you hope to learn from your genetic test … if you have ever had one?

There’s a very nice article today on the MedPage Today web site about the medical value of “at-home genetic testing” (i.e., the sorts of tests available from companies like 23&Me and some others). … READ MORE …

Your genetics can accurately predict your age-related prostate cancer risk

Data from a new study reported in the British Medical Journal discusses a “polygenic hazard score” that can potentially be used to guide screening for aggressive prostate cancer (but only in men of European ancestry at this time). … READ MORE …

Experts create guidelines for screening prostate cancer patients for inherited cancer risk genes

Knowing whether you carry inherited cancer risk genes can help you to make the best decisions for your treatment and for your family. … READ MORE …

Commercially available liquid biopsy data may be misleading

A newly published research letter in JAMA Oncology is entitled “Patient-paired sample congruence between 2 commercial liquid biopsy tests”. The two tests are both said — by the companies that market them — to have high clinical sensitivity and specificity in the identification of specific genetic markers associated with high-risk forms of prostate cancer. … READ MORE …

Germline genetics and different responses to different types of ADT

Three articles in the October 12 issue of JAMA Oncology address the fact that a very specific germline mutation to the so-called HSD3B1 gene affects response to standard forms of initial androgen deprivation therapy and related factors. … READ MORE …